Key result
Primary prevention statins linked to ~60% lower all-cause mortality in older adults.
Why the study?
The effect of statins for primary prevention and specific effective subgroups in the elderly Japanese population remained unclear.
Does statin therapy reduce all-cause mortality in older Japanese adults aged ≥65 years for primary prevention?
Cohort (n=210,052)
Does statin therapy reduce all-cause mortality in older Japanese adults aged ≥65 years for primary prevention?
Effect estimate: HR 0.40 (95% CI 0.33-0.48)
Absolute Event Rate: 3.2% vs 9.5%
p-value: p=<0.0001
Statin therapy for primary prevention in Japanese adults aged ≥65 years is associated with a significant reduction in all-cause mortality, including in those aged 75 to <85 years and those with comorbidities.
Statin use associated with lower mortality in older Japanese adults; hypothesis-generating and requires randomized confirmation before practice change.
Use of statins for primary prevention can reduce all-cause mortality in Asian elderly populations, but their effect and the specific effective subgroups in the elderly Japanese population remain unclear. This study examined the relationship between statin therapy for primary prevention and mortality reduction in older Japanese adults, and investigated the effective subgroups. The cohort study was conducted using the Shizuoka Kokuho Database (SKDB). Data were compared between the statin-treated group and a non-statin-treated (control) group using the inverse probability of treatment weighting (IPTW) method. In the SKDB cohort aged ≥65 years, new statin use was associated with a decreased risk of all-cause mortality (hazard ratio, 0.40; 95% confidence interval [CI], 0.33-0.48) after IPTW adjustment. The risk difference for mortality at 5 years in the statin-treated group compared with that in the control group was 0.05 (95% CI, 0.04-0.06), and the number needed to treat was 21.20 (95% CI, 18.10-24.70). In conclusion, statin use for primary prevention in older adults may reduce the risk of all-cause mortality in the population without atherosclerotic disease. Furthermore, statin use for primary prevention is feasible in patients aged 75 to <85 years and in patients with comorbidities such as diabetes, or dementia.
No takes yet. Share an insight, caveat, or question.
Funaki et al. (2023) conducted a cohort in Primary prevention of all-cause mortality (n=210,052). Statin therapy vs. Non-statin-treated (control) was evaluated on Time to all-cause mortality (HR 0.40, 95% CI 0.33-0.48, p=<0.0001). Statin therapy for primary prevention in Japanese adults aged 65 years and older without atherosclerotic disease significantly reduced the risk of all-cause mortality (HR 0.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: